Intensity Therapeutics’ INT230-6 antitumor effect featured in published study

Intensity Therapeutics (INTS) announced that eBioMedicine, a Lancet Discovery Science journal, has published the company’s phase 1/2 IT-01 clinical study manuscript for the treatment of metastatic or refractory cancers. The manuscript includes the following data results: in heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved: a disease control rate of 75% and median overall survival of 11.9 months; these results compare favorably in phase 1/2 studies that historically reported an mOS of 4 to 7 months. In a metastatic sarcoma subset population receiving only INT230-6, the median overall survival was 21.3 months. In an exploratory analysis comparing patients receiving INT230-6 at a total dose that treated greater than 40% of the patient’s total tumour burden compared to those treated with less than 40% of their TTB, disease control rate was 83.3% vs. 50%, median overall survival was 18.7 months vs. 3.1 months. Improved survival was consistent across a range of low to high tumor burden and tumor sizes. Approximately 20% of patients in the greater than 40% group had uninjected tumors shrink, abscopal effects. Fifteen of 64 patients survived for more than 21 months. INT230-6 induced a qualitative decrease in proliferating cancer cells in injected tumors and a qualitative increase in activated T-cells infiltrating the tumor microenvironment. No dose-limiting toxicities were reported among 64 monotherapy patients; seven patients had a grade 3 with no grade 4 or 5 treatment-related adverse events. Pharmacokinetic results showed that greater than 95% of the active cytotoxic agents remained in the injected tumors.